Stereotaxis has submitted an application seeking CE mark for its robotically navigated MAGiC catheter.
The magnetic interventional ablation catheter has been designed for use in minimally invasive cardiac ablation procedures.
It has been developed to provide precision, stability and flexibility during the testing and treating of cardiac arrhythmias.
Developed in partnership with Osypka, a German medical device company, the catheter is used with Stereotaxis’s robotic systems.
Stereotaxis stated that the MAGiC catheter has many features that help to improve patient safety as well as efficacy, physician experience and procedural efficiency.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataSee Also:
Stereotaxis chairman and CEO David Fischel said: “We are very pleased to reach this important milestone. This is a seminal event for Stereotaxis as a company and for the physician community that is pioneering the frontiers of robotics in electrophysiology.
“Our attention is focused on preparing for commercial launch of the catheter once we receive regulatory clearance.
“We look forward to the positive impact MAGiC can have on patients, physicians, providers and medical progress.”
MAGiC serves as a platform for future innovations and represents the first in a series of interventional devices that are being developed by the firm.
Stereotaxis seeks to make the catheter commercially available for robotic electrophysiology practices in Europe upon receipt of CE mark, which could be before the end of the year.
Separately, the company is also working on the submission of an application to the US Food and Drug Administration (FDA) to begin a prospective investigational device exemption (IDE) trial in the country.
